Exforge HCT is a combination of three different medications that are used to treat high blood pressure. It contains two different types of drugs, which are an angiotensin II receptor blocker (ARB) and a diuretic. The combination of these two medications helps to lower blood pressure more effectively than either medication alone. Exforge HCT has been approved by the U.S. Food and Drug Administration (FDA) and is available in both generic and brand-name forms. This article will provide a comprehensive guide to the benefits of Exforge HCT and how it can help to manage high blood pressure.
Exforge HCT is a combination of two different medications, amlodipine and valsartan. Amlodipine is a type of calcium channel blocker, which helps to relax blood vessels and reduce the amount of pressure that is put on them. Valsartan is an angiotensin II receptor blocker (ARB), which works to block the action of a hormone called angiotensin II. This hormone can cause the blood vessels to narrow, which can raise blood pressure. The third medication in Exforge HCT is hydrochlorothiazide, which is a diuretic. Diuretics help to reduce the amount of fluid in the body, which can reduce the amount of pressure on the blood vessels.
Exforge HCT works by combining the effects of the three medications. The amlodipine helps to relax the blood vessels, reducing the amount of pressure on them. The valsartan blocks the action of angiotensin II, which helps to keep the blood vessels from narrowing. The hydrochlorothiazide helps to reduce the amount of fluid in the body, which reduces the pressure on the blood vessels. All three medications work together to help lower blood pressure.
Exforge HCT can provide a number of benefits for those with high blood pressure. These benefits include:
Exforge HCT can cause a number of side effects, including:
Exforge HCT is not recommended for those with certain medical conditions, including:
1.
Even when they are not paying attention, children are still learning.
2.
Study finds higher breast cancer rates in areas with more air pollution
3.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
4.
New Zealand and Australian breast cancer rates among the highest in the world, global study finds
5.
PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.
1.
Case-Based Learning on Functional Bone Marrow Recovery Following Sequential Immune Challenges
2.
Understanding Cold Agglutinin Disease: Symptoms, Diagnosis, and Treatment Options
3.
Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options
4.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
5.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Understanding Cancer: Early Detection and Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation